Fulvestrant

SAN ANTONIO — The addition of capivasertib to fulvestrant significantly extended PFS among patients with hormone receptor-positive, HER2-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Camizestrant significantly prolonged PFS compared with fulvestrant among postmenopausal women with advanced ER-positive, HER2-negative breast cancer, according to study results.

Endocrine therapies have revolutionized the field of breast cancer, with significant improvements in survival outcomes among patients with hormone receptor-positive disease.

Camizestrant significantly extended PFS compared with fulvestrant among certain postmenopausal patients with advanced breast cancer, according to the agent’s manufacturer.

In this edition, late-stage colorectal, breast cancer diagnoses increase after start of COVID-19 pandemic; chemicals found in hair products increase viability of breast cancer cells in Black women; continued CDK 4/6 inhibition after breast cancer progression may benefit some patients; and more.

In this video, Payal Shah, MD, assistant professor of medicine at the hospital of the University of Pennsylvania, spoke with Healio about the ongoing HOPE trial.

The addition of dalpiciclib to fulvestrant appeared effective and safe for certain patients with advanced breast cancer, according to randomized phase 3 study results presented during the virtual ASCO Annual Meeting.

In this video, Sara M. Tolaney, MD, MPH, discussed updated data from the phase I SERENA-1 trial,which was presented at the virtual San Antonio Breast Cancer Symposium.

BARCELONA, Spain — The addition of ribociclib to fulvestrant significantly extended OS among postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, according to results of the randomized phase 3 MONALEESA-3 trial presented at European Society for Medical Oncology Congress.

BARCELONA, Spain — The addition of abemaciclib to fulvestrant significantly prolonged OS among women with hormone receptor-positive, HER2-negative advanced breast cancer whose disease progressed during endocrine therapy, according to results of the randomized phase 3 MONARCH 2 trial presented at European Society for Medical Oncology Congress.